The Rotation of Disinfectants Principle: True or False? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Rotation of Disinfectants Principle: True or False?
The author defines sanitizers, disinfectants, and antibiotics, and examines the question of whether the rotation of disinfectants is scientifically warranted.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 58-71

46. G. Mayer, "Antibiotics that Affect the Cell Envelope" in Microbiology and Immunology, University of South Carolina, http://pathmicro.med.sc.edu/mayer/antibiot.htm, accessed Jan. 18, 2009.

47. T. Montie and P. Patamasucon. "Aminoglycosides: the Complex Problem of Antibiotic Mechanisms and Clinical Applications," Eur. J. Clin. Microbiol. Infect. Dis. 14, 85–87 (1995).

48. H.J. Busse, C. Wostmann, and E.P. Bakker, "The Bactericidal Action of Streptomycin: Membrane Permeabilization Caused by the Insertion of Mistranslated Proteins into the Cytoplasmic Membrane of Escherichia coli and Subsequent Caging of the Antibiotic inside the Cells: Degradation of these Proteins," J. Gen. Microbiol. 138, 551–561 (1992).

49. H.F. Chambers and M.A. Sande, "Antimicrobial Agents: The Aminoglycosides," in The Pharmacological Basis of Therapeutics, J.G. Hardman et al., Eds. (McGraw-Hill, New York, 1995), pp. 1103–1121.

50. J. Davies and G. Wright, "Bacterial Resistance to Aminoglycoside Antibiotics," Trends Microbiol. 5, 234–239 (1997).

51. K.J. Shaw et al., "Molecular Genetics of Aminoglycoside Resistance Genes and Familial Relationships of the Aminoglycoside-Modifying Enzymes," Microbiol. Rev. 57, 138–163 (1993).

52. E.K. Manavathu et al., "Molecular Studies on the Mechanism of Tetracycline Resistance Mediated by Tet(O)," Antimicrob. Agents Chemother. 34, 71–77 (1990).

53. S.B. Levy et al., "Nomenclature for New Tetracycline Resistance Determinants," Antimicrob. Agents Chemother. 43, 1523–1524 (1999).

54. I. Chopra, "New Developments in Tetracycline Antibiotics: Glycylcyclines and Tetracycline Efflux Pump Inhibitors," Drug Resist. Updat. 5 (3–4), 119–125 (2002).

55. M.C. Roberts, "Tetracycline Resistant Determinants: Mechanisms of Action, Regulation of Expression, Genetic Mobility, and Distribution," FEMS Microbiol. Rev. 19, 1–24 (1996).

56. F. Schluenzen et al. "Structural Basis for the Interaction of Antibiotics with the Peptidyl Transferase Centre in Eubacteria", Nature 413, 814–821 (2001).

57. R. Fernandez-Muñoz and D. Vazquez, "Kinetic Studies of Peptide Bond Formation: Effect of Chloramphenicol," Mol. Biol. Rep. 1, 75–79 (1973).

58. M. Michelinaki et al., "Aminoacyl and Peptidyl Analogs of Chloramphenicol as Slow-Binding Inhibitors of Ribosomal Peptidyltransferase: A New Approach for Evaluating Their Potency," Mol. Pharmacol. 51, 139–146 (1997).

59. M.A. Xaplanteri et al., "Effect of Polyamines on the Inhibition of Peptidyltransferase by Antibiotics: Revisiting the Mechanism of Chloramphenicol Action," Nucleic Acids Res. 31, 5074–5083 (2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here